PDCD1 and nasopharyngeal carcinoma: More recently, 263 patients with metastatic or recurrent NPC were randomly assigned to receive the anti-PD1 antibody camrelizumab or placebo, plus gemcitabine/cisplatin, and progression-free survival (PFS) was significantly longer in the camrelizumab vs. placebo arm [18].